doi: 10.2147/HIV.S24432.
Epub 2012 Dec 5.
Clinical utility and consumer considerations for the use of once-daily nevirapine extended release for HIV infection treatment
Affiliations
- PMID: 23248575
- PMCID: PMC3520460
- DOI: 10.2147/HIV.S24432
Item in Clipboard
Clinical utility and consumer considerations for the use of once-daily nevirapine extended release for HIV infection treatment
HIV AIDS (Auckl).
2012.
Abstract
An extended-release formulation of nevirapine (NVP-XR) has been developed with the aim of simplifying antiretroviral treatment regimens and improving patients' adherence with a single daily intake. The VERxVE and TRANxITION clinical trials have demonstrated the noninferiority of NVP-XR compared with nevirapine immediate-release (NVP-IR) on viral load after 24 and 48 months of treatment. The tolerance profiles of NVP-XR and NVP-IR are similar. Simplifying the treatment dosage for NVP would likely improve adherence to antiretroviral treatments.
Keywords: HIV infection; antiretroviral therapy; efficacy; nevirapine extended release; safety.
Similar articles
-
Twenty-four-week efficacy and safety of switching virologically suppressed HIV-1-infected patients from nevirapine immediate release 200 mg twice daily to nevirapine extended release 400 mg once daily (TRANxITION).HIV Med. 2012 Apr;13(4):236-44. doi: 10.1111/j.1468-1293.2011.00969.x. Epub 2011 Dec 4. HIV Med. 2012. PMID: 22136068 Clinical Trial.
-
Efficacy and safety of nevirapine extended-release once daily versus nevirapine immediate-release twice-daily in treatment-naive HIV-1-infected patients.Antivir Ther. 2011;16(5):759-69. doi: 10.3851/IMP1803. Antivir Ther. 2011. PMID: 21817198 Clinical Trial.
-
Efficacy and safety of switching from nevirapine immediate-release twice daily to nevirapine extended-release once daily in virologically suppressed HIV-infected patients: a retrospective cohort study in Taiwan.BMC Infect Dis. 2017 Apr 11;17(1):261. doi: 10.1186/s12879-017-2371-3. BMC Infect Dis. 2017. PMID: 28399808 Free PMC article.
-
Guidelines for the use of extended-release nevirapine in HIV-infected patients.Expert Opin Pharmacother. 2011 Dec;12(17):2713-8. doi: 10.1517/14656566.2011.630391. Epub 2011 Oct 29. Expert Opin Pharmacother. 2011. PMID: 22035406 Review.
-
Nevirapine once daily: pharmacology, metabolic profile and efficacy data of the new extended-release formulation.Expert Opin Drug Metab Toxicol. 2011 Apr;7(4):495-503. doi: 10.1517/17425255.2011.565331. Epub 2011 Mar 20. Expert Opin Drug Metab Toxicol. 2011. PMID: 21417819 Review.
References
-
- Egger M, May M, Chene G, et al. Prognosis of HIV-1-infected patients starting highly active antiretroviral therapy: a collaborative analysis of prospective studies. Lancet. 2002;360:119–129. - PubMed
-
- Palella FJ, Jr, Delaney KM, Moorman AC, et al. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators. N Engl J Med. 1998;338:853–860. - PubMed
-
- Organisation Mondiale de la Santé. Recommandations rapides: Traitement antirétroviral de l’infection à VIH chez l’adulte et l’adolescent. 2010. [Accessed December 12, 2011]. Available from: http://www.who.int/hiv/pub/arv/rapid_advice_art_fr.pdf.
-
- Thompson MA, Aberg JA, Cahn P, et al. Antiretroviral treatment of adult HIV infection: 2010 recommendations of the International AIDS Society-USA panel. JAMA. 2010;304:321–333. - PubMed
-
- Thompson MA, Aberg JA, Hoy JF, et al. Antiretroviral treatment of adult HIV infection: 2012 recommendations of the International Antiviral Society-USA panel. JAMA. 2012;308:387–402. - PubMed
LinkOut - more resources
Full Text Sources
